<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_abacavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:39 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Abacavir</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">03-31-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>HLA-B*5071 more common in whites and rare in African pts. </li>
<li>In substudy of DART trial in Uganda, suspected hypersensitivity reaction (HSR) reported in only 2% of pts. </li>
<li>When compared to <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>, ABC+ <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> regimen was better tolerated with less treatment discontinuation. </li>
<li>ABC +<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> (+ <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> or <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>) can be considered as an alternative NRTI in patients who can not tolerate <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> + <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>. </li>
<li>If PI-based regimens not available, ABC+<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>+<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> can be considered in women with CD4 &gt;250, HIV-2 infection, or severe reactions to <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> or <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>. </li>
</ul>
<a name="N1079B"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Paula Munderi and the DART Trial Team ;
		Safety of Nevirapine Compared to Abacavir on a Background of Zidovudine/Lamivudine as First-line Antiretroviral Therapy: A Randomized Double-blind Trial ;        
		CROI ;
		2006 ; Vol. 
		109LB ; pp. 
		<br>
<b>Comments:</b>24-week randomized double-blind trial compared the safety of <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> or ABC when combined with zdovudine/lamivudine in 599 ARV-naive patients in Uganda. 6 (2%) on ABC and 14 (4.7%) on <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> developed a serious adverse reaction (HR = "0.41;" 95% CI 0.16-1.08; log rank p = "0.06)." 19/20 of these SAR were consistent with hypersensitivity reaction. Grade 4 toxicities were more common in the <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> treated group (64 ABC vs 91 <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>, p="0.008)," but the majority of these were due to bone marrow suppression. 8 patients (all <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>) developed grade 4 LFTs elevation. <br>
<br>
</li>
</ol>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretrovirals.</li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Ziagen</I>
          </TD><TD valign="top">Abacavir (ABC)</TD><TD valign="top">GlaxoSmithKline </TD><TD>oral</TD><TD>tablet</TD><TD>300 mg</TD><TD>$7.41 per tab</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral</TD><TD>suspension</TD><TD>10 mg/mL</TD><TD>$14 (300 mg)</TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Trizivir</I>
          </TD><TD valign="top">ABC + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A></TD><TD valign="top">GlaxoSmithKline </TD><TD>oral</TD><TD>tablet</TD><TD>ABC 300 mg + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> 300 mg + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> 150 mg</TD><TD>$19.40 per tab </TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Epzicom</I>
          </TD><TD valign="top">ABC + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A></TD><TD valign="top">GlaxoSmithKline</TD><TD>oral</TD><TD>tablet</TD><TD>ABC 600 mg + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> 300 mg</TD><TD>$26.40 per tab</TD>
</TR>
        
<TR>
<TD valign="top"><I>Kivexa </I>(brand name available in Europe)</TD><TD valign="top">ABC + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A></TD><TD valign="top">GlaxoSmithKline</TD><TD>oral</TD><TD>tablet</TD><TD>ABC 600 mg + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> 300 mg</TD><TD>variable</TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden: 2 pills/d (<I>Ziagen, Trizivir</I>) or 1 pill/d (<I>Epzicom, Kivexa</I>)<br>
<br>
<ul>
<li>ABC 300 mg PO bid with or without food (as <I>Ziagen</I> or <I>Trizivir</I>).</li>
<li>ABC 600 mg PO qd with or without food (as <I>Ziagen, </I><I>Epzicom</I>, or<I> Kivexa</I>).</li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>Usual dose <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>Usual dose <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>Usual dose <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>Usual dose <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data-Usual dose likely <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data-Usual dose likely <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>Nausea, abdominal pain, malaise, and headache reported in approximately 7% of pts in clinical trials (8-11% when given with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>).<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>HYPERSENSITIVITY REACTION (HSR) noted in ~4% of pts: fever, rash, fatigue, malaise, GI Sx, myalgias, and arthralgias. Over 93% occur within first 6 wks of therapy, with median time of onset of 11 days. Requires discontinuation, but can continue ABC with close monitoring until Dx certain or likely (Sx generally worsen with each dose). DO NOT RECHALLENGE, since anaphylactic-like reaction and death reported. HSR more common in Caucasians and associated with HLA-DR7, HLA-DQ3, and HLA-B*5701 haplotypes. Genetic testing for HLA-B*5701 (cost $70-80)&nbsp;can essentially eliminates risk of HSR, though pts should still be counseled about HSR before initiation. ABC should NOT be given to pts with positive test. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>MITOCHONDRIAL TOXICITY: <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">Lipoatrophy</A> and <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lactic_acidosis9dee.html?contentInstanceId=432782">lactic acidosis</A> with hepatic steatosis described with NRTI class, although most common with <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A>, <A class="headLines" target="_new" href="../antimicrobial_agents/dapsone00f4.html?contentInstanceId=441413">d4T</A>, ddC, and <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>;unclear whether it occurs at all with ABC, since ABC is one of the least likely NRTIs to cause mitochondrial toxicity&nbsp;<I>in vitro</I><I>. </I>
<br>
<br>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>Not a substrate, inducer, or inhibitor of CYP3A4. No interaction with PIs and NNRTIs. ABC is metabolized by alcohol dehydrogenase and glucoronyl transferase.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">Tipranavir</A>&nbsp;</B></TD><TD valign="top">Decreased ABC AUC by 40%. </TD><TD valign="top">Clinical significance unknown. Use standard dose. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> AUC decreased by 15%.</TD><TD valign="top">Not clinically significant. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>
          </B></TD><TD valign="top">Suboptimal virologic suppression when ABC/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> qd was used as a triple nucleoside regimen without PIs or NNRTIs. However, preliminary analysis of ABC/<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> as nucleoside regimen did not show similar suboptimal results, and no evidence of drug interaction.</TD><TD valign="top">Do not co-administer ABC/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> qd as a triple nucleoside regimen. Minimal data on use of this combination with a 4th agent.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT </A>
          </B></TD><TD valign="top">No significant interaction.</TD><TD valign="top">Use standard dose. </TD>
</TR>
<TR>
<TD valign="top"><B>Alcohol&nbsp;</B></TD><TD valign="top">ABC AUC increased by 41%.</TD><TD valign="top">Clinical significance unknown. No dose adjustment recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Food</B></TD><TD valign="top">ABC AUC was decreased by 5%(NS).</TD><TD valign="top">Administer ABC with or without food.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Methadone
          </B></TD><TD valign="top">Methadone clearance increased by 23%;<BR>ABC: 34% decrease in Cmax.</TD><TD valign="top">Monitor for methadone withdrawal, but dose adjustment unlikely to be necessary.</TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>74V: Intermediate resistance to ABC and ddI. Most common mutation to be selected by ABC/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>-containing regimens without thymidine analog. M184V further decreases susceptibility.</li>
<li>65R: Low-level resistance, and intermediate resistance to ddI, <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>, <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>, FTC. Can be selected by ABC/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>-containing regimens without thymidine analog, though 74V more common. Intermediate ABC and ddI resistance with 65R + 184V. M184V partially restores <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> susceptibility</li>
<li>184V + <U>&gt;</U>3 TAMs: Intermediate-to high-level resistance. Greater ABC resistance with 41L/210W/215Y TAM pathway than with 67N/70R/219 pathway. High-level resistance with&nbsp;<U>&gt;</U>4 TAMs</li>
<li>115F: Can be selected by ABC, and causes low-level resistance. Intermediate resistance with 115F + 184V. </li>
<li>184V: Can cause low-level loss of susceptibility to ABC, but by itself is not associated with clinically relevant resistance. </li>
<li>&nbsp;&nbsp;</li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10A06"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Intracellular phosphorylation to active carbovir triphosphate, which competitively inhibits HIV DNA polymerase.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                Well absorbed with 83% oral bioavailability.</li>
<li>Metabolism and Excretion: 
                81% metabolized by alcohol dehydrogenase and glucuronyl transferase with renal excretion of metabolites; 16% recovered in stool and 1% unchanged in urine.</li>
<li>Protein Binding: 
                50%</li>
<li>Cmax, Cmin, and AUC: 
                Mean steady-state Cmax="3mcg/mL;" AUC="6" mcg hr/mL. Intracellular levels of carbovir triphosphate 100 FM/million cells.</li>
<li>T1/2: 
                Serum: 1.5 hrs; intercellular (carbovir triphosphate):-12-20hrs.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>Usual dose or 200 mg bid (limited clinical data).<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category C: rodent studies demonstrated placental passage. Teratogenic in rodent studies resulting in anasarca, skeletal malformation at 1000 mg/kg dose (35x human therapeutic levels) during organogenesis. However, rabbit studies using 8.5x human therapeutic levels did not result in fetal malformation. No adequate human data, placental passage was 32-66%.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No human data. Breast feeding is not recommended in the U.S in order to avoid post-natal transmission of HIV to the child, who may not yet be infected.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<I>Trizivir</I> (<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/ABC) was equivalent to unboosted <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>-based HAART regimen in pts with baseline VL &lt;100,000, but inferior to <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-based HAART regimens. Since <I>Trizivir </I>(without a PI or NNRTI) is inferior to the gold standard <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-based regimen, it is recommended by the DHHS Guidelines only as alternative regimen when PI- or NNRTI-based regimens cannot be used.&nbsp;Addition of ABC to <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> did not improve virologic response in ART-naive patients. HLA-B*5701 should be ordered in all pts before starting ABC, and ABC should not be given to those who test positive. <br>
<br>
<ul>
<li>Pros: One of most potent NRTIs, with VL reduction of 1.5-2.0 logs in monotherapy;&nbsp;good data on ABC/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> as a well tolerated and effective qd dual-NRTI backbone;&nbsp;no apparent long-term toxicity; development of 74V mutation with failure may allow sequencing to <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>, though clinical data lacking; coformulated with <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> (<I>Epzicom, Kivexa</I>) and with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> (<I>Trizivir</I>); HLA B*5701 pre-sreening essentially eliminates HSR risks discussed below</li>
<li>Cons: Hypersensitivity reaction; requires detailed pre-treatment counseling/education; can be fatal with rechallenge; shorter intracellular half-life than <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>, and no susceptibility benefit with M184V. Less long-term data than with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>.</li>
</ul>
<a name="N10A93"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Gulick RM, Ribaudo HJ, Shikuma CM, et al.;
		Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.;        
		JAMA;
		2006; Vol. 
		296; pp. 
		769-81;
		<br>ISSN:
	        	1538-3598;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16905783&amp;dopt=abstract" target="_new">16905783</a>
<br>
<b>Comments:</b>The continuation of ACTG 5095 compared <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> to <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/ABC/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> in ART-naive pts. No significant differences between 3vs 4-drug regimens; approximately 80% of pts had VL &lt; 50 through 3 yrs. 10% treated with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/ABC/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> had ABC HSR, vs. 7% on <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>. <br>
<br>
</li>
<li>Gallant JE, Rodriguez AE, Weinberg WG, et al.;
		Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.;        
		J Infect Dis;
		2005; Vol. 
		192; pp. 
		1921-30;
		<br>ISSN:
	        	0022-1899;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16267763&amp;dopt=abstract" target="_new">16267763</a>
<br>
<b>Comments:</b>High rate of virologic failure in the <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>+ABC+<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> arm, with 49% experiencing virologic failure compared to 5.4% of pts taking <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>. Among <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>-treated pts for whom virologic data are available, 64% had both the K65R and M184V mutations and 36% had M184V alone. <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/ABC/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> is not recommended as a triple-NRTI regimen, and data minimal for use with a 4th agent.<br>
<br>
</li>
<li>Moyle GJ, DeJesus E, Cahn P, et al.;
		Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.;        
		J Acquir Immune Defic Syndr;
		2005; Vol. 
		38; pp. 
		417-25;
		<br>ISSN:
	        	1525-4135;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15764958&amp;dopt=abstract" target="_new">15764958</a>
<br>
<b>Comments:</b><A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> + once- or twice-daily ABC as part of an ABC/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> backbone were equivalent, with 66% and 68% of pts achieving VL &lt;50, respectively. <br>
<br>
</li>
<li>Gulick RM, Ribaudo HJ, Shikuma CM, et al.;
		Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.;        
		N Engl J Med;
		2004; Vol. 
		350; pp. 
		1850-61;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15115831&amp;dopt=abstract" target="_new">15115831</a>
<br>
<b>Comments:</b>Compared the triple-NRTI regimen of <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/ABC with 2 <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-containing regimens, <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> and <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/ABC + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>. Triple-NRTI arm was stopped early because of a higher rate of virologic failure compared to the <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-based regimens (21% vs 10%, p &lt;0.001). Triple NRTI regimens should only be used as an alternative in pts who cannot take PI or NNRTI-based regimens.<br>
<br>
</li>
<li>DeJesus E, Herrera G, Teofilo E, et al.;
		Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.;        
		Clin Infect Dis;
		2004; Vol. 
		39; pp. 
		1038-46;
		<br>ISSN:
	        	1537-6591;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15472858&amp;dopt=abstract" target="_new">15472858</a>
<br>
<b>Comments:</b>ABC/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> was non-inferior to <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> in a randomized, double-blind study involving 649 naive pts. Response rate (&lt;50) through wk 48 was 70% and 69% in ABC and <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> group, respectively. Pts on ABC/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> had less nausea, vomiting, fatigue, and anemia than pts taking <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>, but more HSR. ABC/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> associated with greater increase in CD4 (209 vs 155) and CD4%.<br>
<br>
</li>
<li>Mallal S, Nolan D, Witt C, et al.;
		Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.;        
		Lancet;
		2002; Vol. 
		359; pp. 
		727-32;
		<br>ISSN:
	        	0140-6736;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=11888582&amp;dopt=abstract" target="_new">11888582</a>
<br>
<b>Comments:</b>This study found an extraordinary association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 alleles and HSR to ABC (OR 822 [43-15675], p&lt;0.0001). Authors concluded that if ABC was withheld in presence of these alleles, prevalence of HSR would decrease from 9-5% to 2.5%. Positive predictive value for HSR 100%, negative predictive value 97%.<br>
<br>
</li>
<li>Staszewski S, Keiser P, Montaner J, et al.;
		Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.;        
		JAMA;
		2001; Vol. 
		285; pp. 
		1155-63;
		<br>ISSN:
	        	0098-7484;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=11231744&amp;dopt=abstract" target="_new">11231744</a>
<br>
<b>Comments:</b><A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> + ABC was equivalent to <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> + unboosted IDV, with 51% in both group achieving VL &lt;400 at 48wks. Trend favoring IDV-based regimen in pts with baseline VL &gt;100,000, with 45% vs 31% achieving &lt;50 (a treatment difference -14% (95% CI, -27% to 0%). Although this trial demonstrated equivalency at &lt;400 endpoint, the decreased potency at high VL suggests lower potency overall. <br>
<br>
</li>
<li>Mallal S., Phillips E., Carosi G., et al. ;
		PREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030) ;        
		4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention, 2007, Sydney Australia ;
		<br>
<b>Comments:</b>This study randomized 1956 abacavir-naive patients to standard of care or screening with HLA-B*5701 test before starting ABC. Incidence of both clinically diagnosed and immunologically confirmed HSR significantly lower in screening arm vs. control arm. No cases of immunologically confirmed HSR observed in prospective screening arm. HLA-B*5701 had a 100% sensitivity. <br>
<br>
</li>
</ol>
<a name="REFERENCED WITHIN THIS GUIDE"></a>
<h2 class="grayLineHeaderBar">REFERENCED WITHIN THIS GUIDE</h2>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/anemia4fdf.html?contentInstanceId=432939&amp;siteId=429188">Anemia</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/changing_or_stopping_art4fdf.html?contentInstanceId=432939&amp;siteId=429188">Changing or Stopping ART</A>
</li>
<li>
<A class="headLines" target="_new" href="fosamprenavirc8f5.html?contentInstanceId=257859&amp;siteId=429188">Fosamprenavir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/initial_regimen_for_arv_therapy4fdf.html?contentInstanceId=432939&amp;siteId=429188">Initial Regimen for ARV Therapy</A>
</li>
<li>
<A class="headLines" target="_new" href="lamivudine4fdf.html?contentInstanceId=432939&amp;siteId=429188">Lamivudine</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/nausea_vomiting4fdf.html?contentInstanceId=432939&amp;siteId=429188">Nausea/Vomiting</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/nutrition_care_and_support4fdf.html?contentInstanceId=432939&amp;siteId=429188">Nutrition Care and Support</A>
</li>
<li>
<A class="headLines" target="_new" href="tenofovir4fdf.html?contentInstanceId=432939&amp;siteId=429188">Tenofovir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/toxicity___side_effects__switching_therapy__zambia_spec4fdf.html?contentInstanceId=432939&amp;siteId=429188">Toxicity &amp; side effects: switching therapy (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/tuberculosis__active__zambia_specific_4fdf.html?contentInstanceId=432939&amp;siteId=429188">Tuberculosis, Active (Zambia specific)</A>
</li>
</ul>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_abacavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:39 GMT -->
</html>
